PuSH - Publication Server of Helmholtz Zentrum München

Journal browsing

93 Records found.
Zum Exportieren der Ergebnisse bitte einloggen.
Lay all publications on this page into basket
1.
Erdur, A.C.* et al.: Improving risk assessment of local failure in brain metastases patients using vision transformers - A multicentric development and validation study. Radiother. Oncol. 210:111031 (2025)
2.
Zamboglou, C.* et al.: oDigital pathology biomarkers for guiding radiotherapy-based treatment concepts in prostate cancer - a systematic review and expert consensus. Radiother. Oncol. 210:111039 (2025)
3.
Kern, J.* et al.: Identification of the unfolded protein response pathway as target for radiosensitization in pancreatic cancer. Radiother. Oncol. 191:110059 (2024)
4.
Peeken, J.C. et al.: Development and benchmarking of a Deep Learning-based MRI-guided gross tumor segmentation algorithm for Radiomics analyses in extremity soft tissue sarcomas. Radiother. Oncol. 197:110338 (2024)
5.
Buchner, J.A.* et al.: Identifying core MRI sequences for reliable automatic brain metastasis segmentation. Radiother. Oncol. 188:109901 (2023)
6.
Linge, A.* et al.: The value of subcutaneous xenografts for individualised radiotherapy in HNSCC: robust gene signature correlates with radiotherapy outcome in patients and xenografts. Radiother. Oncol. 191:110055 (2023)
7.
Scharl, S.* et al.: Salvage radiotherapy is effective in patients with PSMA-PET-negative biochemical recurrence- results of a retrospective study. Radiother. Oncol. 184:109678 (2023)
8.
Buchner, J.A.* et al.: Development and external validation of an MRI-based neural network for brain metastasis segmentation in the AURORA multicenter study. Radiother. Oncol. 178:109425 (2022)
9.
Diehl, C. et al.: nTMS-derived DTI-based motor fiber tracking in radiotherapy treatment planning of high-grade gliomas for avoidance of motor structures. Radiother. Oncol. 171, 189-197 (2022)
10.
Löck, S.* et al.: Biomarker signatures for primary radiochemotherapy of locally advanced HNSCC - hypothesis generation on a multicentre cohort of the DKTK-ROG. Radiother. Oncol. 169, 8-14 (2022)
11.
Patil, S.* et al.: Analyses of molecular subtypes and their association to mechanisms ofradioresistance in patients with HPV-negative HNSCC treated bypostoperative radiochemotherapy. Radiother. Oncol. 167, 300-307 (2022)
12.
Patil, S.* et al.: Development and validation of a 6-gene signature for the prognosis of loco-regional control in patients with HPV-negative locally advanced HNSCC treated by postoperative radio(chemo)therapy. Radiother. Oncol. 171, 91-100 (2022)
13.
Combs, S.E. et al.: ESTRO ACROP guideline for target volume delineation of skull base tumors. Radiother. Oncol. 156, 80-94 (2021)
14.
Nguyen, L. et al.: Impact of DNA repair and reactive oxygen species levels on radioresistance in pancreatic cancer. Radiother. Oncol. 159, 265-276 (2021)
15.
Peeken, J.C. et al.: MRI-based delta-radiomics predicts pathologic complete response in high-grade soft-tissue sarcoma patients treated with neoadjuvant therapy. Radiother. Oncol. 164, 73-82 (2021)
16.
Borm, K.J.* et al.: Irradiation of regional lymph node areas in breast cancer - Dose evaluation according to the Z0011, AMAROS, EORTC 10981-22023 and MA-20 field design. Radiother. Oncol. 142, 195-201 (2020)
17.
Akhgar, J.* ; Peeken, J.C. ; Pigorsch, S.U.* & Combs, S.E.: Response prediction of palliative radiotherapy to painful spinal bone metastases. Radiother. Oncol. 133, S879-S880 (2019)
18.
Bartzsch, S.: Compact microbeam sources and microbeam treatment planning. Radiother. Oncol. 133, S176-S177 (2019)
19.
Bierbaumer, D.* et al.: Impact of diabetes on outcome and toxicity of neoadjuvant (chemo)radiation for rectal cancer. Radiother. Oncol. 133, S794-S795 (2019)
20.
Bierbaumer, D.* et al.: Impact of diabetes on outcome and toxicity of chemoradiation for esophageal squamous cell carcinoma. Radiother. Oncol. 133, S780-S780 (2019)